ArticleBMC medicine2022
Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors.
Pei Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
32 papers cite it
this papertrialcites it